Renal Toxicity Outcomes for Pediatric Patients Receiving Cidofovir for the Treatment of Adenovirus Infections

Introduction Conclusions Background: Adenovirus (AdV) infection is accompanied by significant morbidity and mortality in high-risk pediatric patients. Treatment options are considerably limited by toxicity. Nephrotoxicity has been associated with cidofovir therapy, although most pediatric studies report little or no morbidity with its use. Pharmacokinetic (PK) data for children is limited; a pediatric PK study determined that cidofovir half-life was significantly longer in children than adults (Brown, 2015).